December 18, 2023
Eisai CEO Haruo Naito Eisai CEO Haruo Naito said on December 15 that the company’s Alzheimer’s therapy Leqembi (lecanemab) is expected to be approved in Europe and China by the end of March next year following its launches in the...read more